BioCurex Enters Collaboration Agreement With Largest Cancer Research Center in Russia.

RICHMOND, British Columbia -- BioCurex Inc. (OTCBB:BOCX) announced today that it has signed a collaboration agreement with the Blokhin Cancer Research Center in Moscow, Russia, for further development and evaluation of its RECAF(TM) technology.

This new phase of the BioCurex/Blokhin collaboration is centered on the use of the RECAF marker for cancer screening, diagnosis and follow-up of treated patients using serum samples. The Center comprises 4 separate Institutes, including a 1,600 bed hospital devoted to cancer patients. It is one of the largest in Europe employing 700 scientists and 2,000 medical personnel.

Dr. Moro, CEO of BioCurex stated: "This collaboration is very welcome because we shall have direct access to patients, to their final diagnosis, biopsies, and serum in a comprehensive way. The access to hundreds of well documented samples, as well as the opportunity to do prospective studies is extremely important. It will allow us to characterize and adjust the assays to the practical needs in the laboratory routine, as well as gather data to present to regulatory agencies. We can assert the usefulness of RECAF in the natural environment of the clinical laboratory within a cancer center."

Professor Kushlinsky, Head of the Clinical BioChemistry Laboratory of the Blokhin Cancer Research Center stated: "As an Oncology Center whose vision is to see the implementation of the diagnostic tests for the early detection of cancer, we are pleased to be working with BioCurex. The RECAF technology has the potential to become a diagnostic tool, which may improve the course of cancer detection and advance health care. BioCurex's studies to date have produced some promising results, which were presented at ISOBM 2004, 2005 and 2006. We are ready to continue our collaboration with the aim of further evaluation of the utility of RECAF and we look forward to combining our resources and scientific knowledge to bring this diagnostic technology to its realization."

The Blokhin Cancer Research Center is part of the American-Russian Cancer Alliance, which also includes the University of Maryland Greenebaum Cancer Center in Baltimore, Maryland, the Kurchatov Institute and the Fox Chase Cancer Center in Philadelphia, Pennsylvania. The US National Cancer Institute (NCI) provides the infrastructure for the Alliance.

BioCurex has already established an international presence with its Scientific Advisory Board. The board includes talented and recognized persons from Canada, USA, France, Russia, Spain and Japan. Cancer is an international concern with extensive research and development occurring in many centers of the world. BioCurex is pleased to expand the knowledge of RECAF technology to the international community.

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF(TM) Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAF(TM) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.

To read more about the Company, please visit the News section in our web site (www.biocurex.com).

Note:

The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.